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A variant of the protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene is known
to be associated with susceptibility to autoimmune diseases and bacterial infections as it
acts as an important regulator of T-cell activation. The objective of this study was to eval-
uate whether PTPN22-C1858T polymorphism is associated with the resistance to pul-
monary tuberculosis (PTB). Single-nucleotide polymorphism of PTPN22-C1858T
(rs2476601) was genotyped in 124 patients with PTB and 130 healthy controls from India
using restriction fragment length polymorphism and direct sequencing of the amplified
DNA. The frequencies of genotypes CC, CT, and TT were 100%, 0%, and 0%, respectively,
in PTB; and 99.2%, 0.8% and 0%, respectively, in healthy control individuals. These values
did not differ significantly between the patients and controls. The mutant allele C1858T
was found to be a rare allele in Indian population.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Tuberculosis (TB), an infectious disease caused by Mycobac-
terium tuberculosis (Mtb), is a major global health problem.
The number of TB cases reported worldwide is on the rise
partly due to development of multidrug-resistant Mtb. TB is
also the leading cause of death from infectious diseases,especially in Asia and Africa [1]. According to the World
Health Organization Global Tuberculosis Report 2015, TB ranked
alongside human immunodeficiency virus as a leading cause
of death. In 2014, there were an estimated 9.6 million new TB
cases, of which 1.5 million deaths were recorded, indicating
the high prevalence of this disease. Globally, India has the lar-
gest number of TB cases—23% of the global total followed byesh, India.
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lion TB cases were reported from India [2].
TheWorld Health Organization estimated that one-third of
the global population is infected with Mtb, but only 5–10%
among them develop the clinically evident disease [3]. This
indicates that along with the infective agent other factors also
play a role in developing clinically evident disease. Variability
in TB susceptibility was demonstrated in Germany, wherein
accidental injection of live Mtb instead of Bacillus Calmette–
Gue´rin vaccine caused some infants to become seriously ill,
whereas others showed no symptoms at all [4]. This finding
indicates a clear genetic predisposition as one of the host fac-
tors influencing risk factors for the development of TB [5–7].
Access to genetic data using various studies is an impor-
tant aspect of identifying new genetic associations through
genome-wide association studies [8]. Genome-wide associa-
tion studies have been successful in identifying genetic vari-
ants that contribute to complex human traits in diverse
populations [9]. Several genes are reported to have been asso-
ciated with TB pathogenesis such as protein tyrosine phos-
phatase nonreceptor type 22 (PTPN22), TLR2, vitamin D
receptor (VDR), and cytokine genes (interleukin-10 [IL-10], IL-
6, interferon-c, tumor necrosis factor-a, and tumor growth
factor-b1) [10].
Protein tyrosine phosphatases are involved in maintaining
the T cells in the resting stage and are also responsible for
bringing back the activated T cells to the resting phenotype
in the absence and presence of antigen, respectively [11,12].
In this study, we focused on Lyp encoded by PTPN22. Lyp, a
cytosolic phosphatase, is mainly expressed in hematopoietic
cells [13,14]. By dephosphorylating many proteins and
enzymes in early T-cell receptor signal cascade, Lyp acts as
a negative regulator of T-cell receptor signaling [15,16] and
is involved in immune and inflammatory responses; addition-
ally, its levels are increased in cells that participate in the
immune response against Mtb [17]. Previous studies have
identified the physiological association between a missense
C1858T (R620W) mutation in PTPN22 and autoimmune dis-
eases such as rheumatoid arthritis [15,18,19], type 1 diabetes
[20–23], systemic lupus erythematosus [24], and Graves’ dis-
ease [25,26]. Vang et al. [16] have reported that the missense
allele (C1858T allele) is a gain-of-function variant. It has also
been reported that the C1858T allele of PTPN22 is associated
with a higher incidence of bacterial pulmonary infections in
patients with chronic mucocutaneous candidiasis [27]. How-
ever, the C1858T allele has been shown to play a protective
role in pulmonary TB in various populations [28–31]. Interest-
ingly, it has also been reported that the C1858T allele of
PTPN22 is not associated with TB in an Iranian population
[32]. Studies in Indian population have evaluated the associa-
tion between the C1858Tallele of PTPN22 and various diseases
such as type 1 diabetes [33,34], sporadic idiopathic
hypoparathyroidism [35], and rheumatic heart disease [36],
but no such association studies were so far performed for
TB patients. The differences in the results concerning the
association of the C1858T allele of PTPN22 with different dis-
eases in various populations necessitated the present investi-
gation in Indian population. This study aims to investigate
the association between the single-nucleotide polymorphism(SNP) C1858T allele of PTPN22 and pulmonary TB in a sample
of Indian population.
Materials and methods
Study subjects
Whole-blood samples (2 mL) were collected from 124 pul-
monary tuberculosis (PTB) patients at Jayalakshmi Memorial
Chest Hospital, Kadapa, Andhra Pradesh, India (60 male
patients and 64 female patients; mean age: 45.36 ± 5.92 years).
Acid-fast bacilli in sputum samples, chest X-ray examination,
and Mantoux and fine-needle aspiration cytology tests were
performed to confirm the disease, although the patients were
already undergoing treatment. We have randomly selected
130 age- and sex-matched unrelated healthy controls (60
males and 70 females; mean age: 40.25 ± 7.62 years). Individu-
als recruited to the health control group had no previous his-
tory of TB. All patients gave written informed consent. The
Ethics Committee of the institute approved this study.
Genomic DNA extraction from whole blood
Genomic DNAwas extracted from EDTA-treated frozen whole
blood by a rapid nonenzymatic method [37]. Genotyping of
PTPN22-1858C/T SNP (rs2476601) was performed by restriction
fragment length polymorphism in the amplified DNA. A frag-
ment of the PTPN22 gene was amplified using specific primers
(sense and antisense primers were 50-GATAATGTTGCTT
CAACGGAATTTA-30 and 50-TCACCAGCTTCCTCAACCACA-30,
respectively). The XcmI site generated by the PTPN22-1858C/
T transition mutation was used for the detection of SNP.
The amplified fragment was then digested with XcmI (New
England Biolabs, Beverly, MA, USA) for detecting the SNP. A
10-lL aliquot of the polymerase chain reaction (PCR) product
was digested overnight with 10 U of XcmI at 37 C. After incu-
bation, the restriction digestion mixture was electrophoresed
on a 1.2% agarose gel in 1 Tris–acetate–EDTA buffer for 1 h at
125 V. The genotype of all patients and controls obtained
using the restriction fragment length polymorphism-PCR
assay was verified by direct sequencing using the sense
primer.
Statistical analysis
Allele frequencies of PTPN22 were counted directly. The p val-
ues were two tailed and the statistical significance was noted
at the .05 level. Fisher’s exact test and Spearman correlation
test were performed using GraphPad Prism 5.0 (GraphPad
Software, La Jolla, CA, USA).
Results
The presence of restriction endonuclease site for XcmI
(CCANNNNNNNNNTGG) in the PCR-amplified product indi-
cates the presence of mutant allele in PTPN22. In samples
from heterozygous subjects with mutant T allele, the 215-bp
products were digested into 170- and 45-bp fragments.
Patients with 1858C alleles did not have any restriction site
Fig. 1 – XcmI digestion patterns of the PTPN22-C1858T
polymorphism. A 215-bp fragment of the PTPN22 gene
region was amplified by polymerase chain reaction (PCR)
using genomic DNA as template. The PCR product was
digested with XcmI restriction endonuclease and then
separated on a 1.2% agarose gel and stained with ethidium
bromide and visualized using ultraviolet light. Lanes 1 and
3 = undigested amplified product of PTPN22. Lane
2 = PTPN22-amplified product digested with XcmI
(heterozygous) showing 215-bp (upper arrow) and 170-bp
(lower arrow) fragments. Lane 4 = PTPN22-amplified product
digested with XcmI (homozygous). Lane 5 = 100-bp DNA
ladder. bp = base pair.
Fig. 2 – DNA sequencing for part of the PTPN22 gene. (A)
Genotype CC. (B) Genotype CT. The arrow in panel B
indicates the position of the single-nucleotide
polymorphism where the overlapping of two peaks
(heterozygous) can be observed.
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digestion of the PTPN22-amplified product with XcmI revealed
that only one healthy individual was a heterozygous mutant
for the C1858T allele (Lane 2) and none of the patients carried
the missense allele (Fig. 1).
The frequency of occurrence of the mutant genotype (CT
or TT) among PTB patients was 0% (0/124) and there was
one heterozygous (CT) mutant (1/130 = 0.8%) in the healthy
controls (p > .99; Table 1). The frequency of the mutant allele
was found to be 0% in the patient group and 0.38% in the
healthy control group (Table 1). Furthermore, the mutation
was confirmed by direct sequencing of the PCR-amplified
product. For the heterozygous genotype with the mutant T
allele, two peaks overlapped each other in a chromatogram
(Fig. 2), which indicated the presence of both C and T alleles.Table 1 – Genotype and allele frequencies of the PTPN22 of
the C1858T polymorphism in pulmonary tuberculosis.
Genotype Patients
(pulmonary tuberculosis)
Healthy controls
CC 100% (124/124) 99.2% (129/130)
CT 0% (0/124) 0.8% (1/130)
TT 0% (0/124) 0% (0/130)
Fishers exact test, p > .99
Alleles
C 100% (248/248) 99.62% (259/260)
T 0% (0/248) 0.38% (1/260)Discussion
In this study, we found no association between the genotypic
and allelic frequencies of the PTPN22-C1858T gene polymor-
phism and susceptibility to PTB in a sample of the Indian pop-
ulation. We have detected only one heterozygous mutant (CT)
in healthy control samples and no individuals with homozy-
gous mutant (TT) were detected among patients and controls.
The low mutant allele frequency of PTPN22 was also reported
in another study in a different disease in the Indian popula-
tion [35].
Some of the earlier studies reported a significant associa-
tion between the T allele and PTB [28,29]. Similar to previous
studies on Moroccan population [29], Colombian population
[28], and Iranian population [32], a sample of the Indian pop-
ulation also showed the absence of TT genotype in TB cases.
The aforementioned studies [28,29] suggest a potential pro-
tective role of the T allele in TB. However, in contrast to the
previous studies, the distribution of T allele in this study
was very low. It has been reported that the PTPN22-C1858T
polymorphism is not involved in susceptibility to Brucella
melitensis, an intracellular pathogen, which causes human
brucellosis [38]. The observations suggest that PTPN22-
C1858T confers resistance to TB while also increasing suscep-
tibility to Gram-positive bacteria. In this present study, the
mutant allele C1858T was identified as a rare allele at a fre-
quency of 0.0019 (1/508) and as such it cannot be used as a
marker for PTB in Indian population.
In conclusion, our study results found that PTPN22-C1858T
is not associated with the susceptibility to PTB in Indian
population.
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